ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM
Abstract Number: 2083
A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy
1:00PM-3:00PM
Abstract Number: 2082
A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy
1:00PM-3:00PM
Abstract Number: 2088
Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort
1:00PM-3:00PM
Abstract Number: 2068
All-Cause Mortality in a Systemic Lupus Erythematosus Cohort
1:00PM-3:00PM
Abstract Number: 2098
Analysis of Cutaneous Lupus Hospitalizations: A United States National Population-based Study
1:00PM-3:00PM
Abstract Number: 2059
Association of Hydroxychloroquine with the Incidence of Infectious Disease in Systemic Lupus Erythematosus: Data from the LUNA Registry
1:00PM-3:00PM
Abstract Number: 2097
Association of Renal Biopsy NIH Activity and Chronicity Scores with Clinical Outcomes in a Cohort of Patients with Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 2103
Association of Telomere Length with Phenotypic Frailty in Adults with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2091
Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network
1:00PM-3:00PM
Abstract Number: 2105
Comparison of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) and the FRAIL Scale for Identifying Frailty Among Individuals with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2081
COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave
1:00PM-3:00PM
Abstract Number: 2084
COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2053
Current State and Completeness of Reporting Clinical Prediction Models Using Machine Learning in Systemic Lupus Erythematosus: A Systematic Review
1:00PM-3:00PM
Abstract Number: 2106
Disparities of African American Mortality Trends in South Carolina Lupus Cohort
1:00PM-3:00PM
Abstract Number: 2077
Does Early Complete Remission Preclude Adverse Outcomes in Lupus Nephritis?
1:00PM-3:00PM
Abstract Number: 2102
Does Remission According Definition of Remission in SLE (DORIS) 2021 Match the Treating Rheumatologist Judgment? Analysis at Recruitment of a Prospective Study of 500 SLE Patients from a Spanish Multicenter Cohort
1:00PM-3:00PM
Abstract Number: 2099
Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers
1:00PM-3:00PM
Abstract Number: 2085
Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study
1:00PM-3:00PM
Abstract Number: 2100
Employment Trajectory of Canadian Young Adults with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2080
Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample
1:00PM-3:00PM
Abstract Number: 2072
Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index
1:00PM-3:00PM
Abstract Number: 2090
Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids (SLEDAI-2KG) on Patient Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)
1:00PM-3:00PM
Abstract Number: 2058
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2092
Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE
1:00PM-3:00PM
Abstract Number: 2093
Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort
1:00PM-3:00PM
Abstract Number: 2070
Health-Related Quality of Life Across the Spectrum of Connective Tissue Diseases: A Latent Profile Analysis
1:00PM-3:00PM
Abstract Number: 2061
Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis
1:00PM-3:00PM
Abstract Number: 2060
Increased Risk of Adverse Renal Outcomes in Patients of African Ancestry with Systemic Lupus Erythematosus (SLE) – Role of APOL1
1:00PM-3:00PM
Abstract Number: 2056
Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis
1:00PM-3:00PM
Abstract Number: 2066
Measuring Sexual Dysfunction as an Indicator of Frailty in Systemic Lupus Erythematosus Population
1:00PM-3:00PM
Abstract Number: 2063
Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
1:00PM-3:00PM
Abstract Number: 2078
Mesangial Lupus Nephritis: Long Term Outcomes
1:00PM-3:00PM
Abstract Number: 2101
Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study
1:00PM-3:00PM
Abstract Number: 2057
Outpatient Visit Adherence and Impact on Disease-related Morbidity in Childhood-onset Systemic Lupus Erythematosus (cSLE)
1:00PM-3:00PM
Abstract Number: 2074
Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study
1:00PM-3:00PM
Abstract Number: 2062
Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US
1:00PM-3:00PM
Abstract Number: 2094
Predictors of Health-Related Quality of Life (HRQoL) in Adults with Juvenile- and Adult-onset Systemic Lupus Erythematosus: Results from a Multiethnic US Cohort (LUMINA)
1:00PM-3:00PM
Abstract Number: 2067
Predictors of Organ Damage Accrual by Domains
1:00PM-3:00PM
Abstract Number: 2107
Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension
1:00PM-3:00PM
Abstract Number: 2087
Prospective Study of Clinical, Laboratory, and Patient-Reported Outcomes of Patients with Systemic Lupus Erythematosus Undergoing Total Hip and Total Knee Arthroplasty
1:00PM-3:00PM
Abstract Number: 2086
Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2069
Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
1:00PM-3:00PM
Abstract Number: 2075
Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids
1:00PM-3:00PM
Abstract Number: 2096
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2055
SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?
1:00PM-3:00PM
Abstract Number: 2079
Survey to Prioritize and Generate Domains in Preparation to Update the OMERACT Core Domain Set for Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2065
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
1:00PM-3:00PM
Abstract Number: 2089
The Implication of Skin Involvement on Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
1:00PM-3:00PM
Abstract Number: 2073
The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies
1:00PM-3:00PM
Abstract Number: 2071
The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), American College of Rheumatology (ACR), and Lupus Foundation of America (LFA) Damage Index Revision – Item Generation Phase
1:00PM-3:00PM
Abstract Number: 2104
The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE
1:00PM-3:00PM
Abstract Number: 2054
Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
1:00PM-3:00PM
Abstract Number: 2064
Trajectories of Disease Activity in a Longitudinal Registry of Pediatric SLE
1:00PM-3:00PM
Abstract Number: 2076
Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
1:00PM-3:00PM
Abstract Number: 2052
Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
1:00PM-3:00PM
Abstract Number: 2095
Validation Analysis of the Physician Global Assessment (PGA) Scale in Patients with Systemic Lupus Erythematosus Included in RELESSER-PROS Registry

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology